Stoke Therapeutics Inc
NASDAQ:STOK

Watchlist Manager
Stoke Therapeutics Inc Logo
Stoke Therapeutics Inc
NASDAQ:STOK
Watchlist
Price: 8.6 USD 6.04% Market Closed
Market Cap: 455.5m USD

EV/EBITDA
Enterprise Value to EBITDA

-1.9
Current
-2.5
Median
3.9
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-1.9
=
Enterprise Value
216.1m USD
/
EBITDA
-115m USD
Market Cap EV/EBITDA
US
Stoke Therapeutics Inc
NASDAQ:STOK
455.3m USD -1.9
FR
Pharnext SCA
OTC:PNEXF
6T USD -210 453.3
US
Abbvie Inc
NYSE:ABBV
373.8B USD 17.2
US
Amgen Inc
NASDAQ:AMGN
168.4B USD 16.6
US
Gilead Sciences Inc
NASDAQ:GILD
138.9B USD 11.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
129.7B USD 26.5
US
Epizyme Inc
F:EPE
94.1B EUR -536.9
AU
CSL Ltd
ASX:CSL
121.1B AUD 17.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
73.1B USD 10.9
US
Seagen Inc
F:SGT
39.3B EUR -61.4
NL
argenx SE
XBRU:ARGX
32.9B EUR 317.6
EBITDA Growth EV/EBITDA to Growth
US
Stoke Therapeutics Inc
NASDAQ:STOK
Average EV/EBITDA: 59.6
Negative Multiple: -1.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -210 453.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17.2
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.6
14%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
11.3
6%
1.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.5
16%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -536.9 N/A N/A
AU
CSL Ltd
ASX:CSL
17.2
12%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.9
17%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.4 N/A N/A
NL
argenx SE
XBRU:ARGX
317.6
168%
1.9

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-1.8
2-Years Forward
EV/EBITDA
-1.5
3-Years Forward
EV/EBITDA
-1.4